Angiotensin-converting enzyme inhibitors after myocardial infarction: Indications and timing  by Ball, Stephen G. et al.
:  
Sttidies of Left Ventricuiaf D@nctian (S~LVD) teal, iti 
which patients were sehxted QII the basis of.tiduced ejection 
fraction, @nly rhrrse who tol@r@d a: 3: to. 7-&y, treatmen’t 
period with enaIapdl and a 2-week placebo .withdrawal phase 
were randomized. Hypotension appartrtt both on ‘initial ad- 
ministration and with long-term treatment was ‘again dgcu- 
mented but seemed a small disadvantage-against the-ktential 
for gain in longevi~ and ~&e&being.. In the% @udies and ‘the- 
Se&d Veterans Heart .l?aiture Trial (V-Hem ii) (4) (Om- 
pafing bydrafazine and isosorbih dinitratc With enalapril), the 
vast majority Of patients were rG%@zed many month% aft&. 
myocardial infarciidn. The, ,appropcate tie of arigiotonsin- 
c&wcrting ‘enzyme inhibitors .immediately after myocardial 
infarction, where, for example, unpredictable decrease% iti 
blood presqemighi have particular. disadvantages, $as the& 
ioie, not addressed by these trials. : 
: Two majo; studies, the Survival and- Ventricular +arqe- 
mctlt (SAVE j:(5 j a@ CbNSENSUS- il.(h) trials, hi&c +~a%- 
ined the effect df angiotensin-conve’rting cqme inhibiti: tn on 
mbrtality aft& my&ardial irtfarction and were @Wshe& to- 
gether. in 19%;’ ‘We vpresented a ,cautious approaih in a 
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Tab& i. : Mortality IFate $,I&& With &qiotensin-Converting Enzyme Irihibitors 
::, :_ : .; 
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.: Study No. of Drug 
~toome, .’ :, 
,’ (r&no.) Fls us+ 
‘2 Risk Rcdtii& *:I 
‘fime al Initiation* Follow-Up : ,Mortality Izate (95% Cl) Value 
SAVE (5) 231 cai J-16 d’@v 11 d) $2 mo : PI 25s,,Cap 20% ‘i9%(3-32%): -’ 
mN~ENsus ir (6) .5,090 
1’ “0.019 
Eilal Immediate (av 15 h) 6ma ‘PI 10.2%. Enal il.oa :JOs iacfe;rse : 0.26 
. : (7% rcdllct~ I 
29*increase) :y’ 
AIRfi (9). 2JMl6 Ram MOd(avSd) av IS mc. min 6 ma PI 2.3% Ram 179 ,?7% (1 I-40?,) om2 
ISIS-It 54x4 .‘cap <Zdh 35 d, PI 7.33%. CAP 6.87% ‘b% @If’-12%) ‘0.113 
GISSI-j (131 1ww Lis ~24 h hwk Con 7.1%. Lis 6.3% I I% (I-m) 0.03 
aimRet lI,W5 Cap 46 h Bd PI r),7%, Cap 9.49 - NS 
‘iUKEt 1,749 TiINl 3-7d min 24 mo, W-X ma PI 42.3%~~ Tran 34% 22% (9133%) 0.0014 
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,+Time after: myoc@ti infarction to strut of treatment. iISTS-4 and Chinese study data are b&d ,a ini@l preSent&on af resulti at the 66th Annual S&&ic 
!Sessim of the Amhican Wearl Associaiion, Allanta. Ge&ia, lrlovember 1m Trandolqril Car&c Evaluation .(TRACE) resdts were presented at Tbc Wo&i 
Congras nf Catdiolagv< Berlin, Germany. September 1494. av = average; Cap = captopril; Cl = confidence interuk Con r control gmup (not plaeba contralkd); 
: d = days; Enal = enrrlapril; L4s = Iisinopiil; min = -minimum; PI = pta&; F’ts = patients; Ram = ramipril; ref. = referencq Trao = trando!opriL 
highly selected &up, and the other was designed. on the SAVEI and CONSENSUS’Ii. Come& 
P&I&& that the-ear& and widespread use of an-angiotensin- 
cunverting &zyme.inh~~i~or would offer most overali benefit. 
The apparently conflicting findings of these @JO trials made it 
d#icuji for thti clinician to decide how ‘bqt to use angiotensin- 
converting enzze inhibitors in the immediate period after 
myocardiai infarction. 
:  :  .’ 
The rationale Car both of these studies ‘.G:: t!,at angiotensin-. 
converting enzyme inhibitiori would b&nzficially affect “infarct 
expansion and subsequent remodeling” (7). H&ever, the 
strategies adopted in the two studies were very different. +fhe 
SAVE study identified patier+ whose infarct had been suffi- 
cient to cause considerable and measurable ventricular dam- 
age but, at the iime of randomization, it was not causing over! 
Qver 2,000 patients &th a myocardial infarction were 
sefected for ,the SAVE study on the basis of a reduced 
radion$idt ,ejection fraction (<do%). At randomizaeion, 
patients had n@ overt signs or symptoms of heart failure, 
-although 3% had exhibited some evidence of heati failure 
bkfore this ~ime.~~ test dgse qi tgppnopril was <ien+ and thase 
who could to&&e this dos+ w&e Started on long-ttiti Ireat- 
ment G&h capto@il (3 to id &ys, &rage 11) after &yo&rdial 
infarction, After in average fobllow-up of 42 months, the risk 
reduction in total mortality fate was’ 19% (95% confidence 
interyd’ [Cl] 3% :6.3&5) (Table 1). i 
:>, 
The SAVE Study 
clinical failure. All patients had an exetise test to exclude 
ischemia, with appropriate coronary angiography and, if iucli- 
cated, coronary angiopI*ty or coronary artery bypass surgery 
Some 60% Bad angiog-raphy, and 255’5 had revascularization 
before entry into the trial. Trea&nent with captopril was 
started in a 3- to llrc?ay wir.20~ (the average time of random- 
ization was 11 days). Thrjmbolpis rates weti !ow in the-SAVE 
study, acsi a high:pioportikln of.paieh& had Q w;rave:mjrocar- 
dial infarctions.. LuGma experinj& Bnd limited data in ,hu- 
mans support the notion that “full thick&s” infaiction with 
failure to reperfust forms the optimal substrate for infarct 
expansioy and subs&juent remodeling. .P+~nts selected for 
the SAVE study are likely to have been parttculariy sus&ptible 
to tientrietar enlargement; however, the tiining of dosing ,in 
SAVE ~upport5 a benefit of angiotensin-co~vertiirg enzyme 
inhibitors on long term ventficuiar remtideling’rathet than t+ 
eaili~r~odcui-&~ce of infarct elq?a+m. .- .. ! -1:. I ” 
in cuntr&& to S.SvE, the: +n&raiion di the, +a+ila{ 
in i2ONSEN3JS ]f.was oiiaveragk within l-5 h &f the onset :cif 
chest pain of the p&Ming infarction, aid i&venous the&’ 
‘&py was gi\len” to .ensure ‘rapid and &mediate angio$nsiri- 
converting qzyme inhi@oti .at :-the end of @usion. of t&z 
thr&bolytic agent. Such an imrfiediate intervention pr?vi&d 
khe: opprttity .to mod&y &ly ifif@ e&m&n aS’ well as 
longlteti, &&c&r .:r+mod&ng. iCo@epttially, it seemed, 
therefore; th& ,,the potential For b&&t .$o@d. have bqen- 
in&sed by immediate intenieatioti. ! 
Al! patietit&&er m$x&dial infarctioit.unIess:hypotensive, 
,usuc4Iy immediately after.zhe completionof thrombqlysis, were 1 
@Yea placeb$ c&: intravenous en’alapril& followed. by, oral 
therany Within an a&ragq of !5 h of q&t of chest. pain. The 
CONSENSUS II trial was ended preniaturely ;liter:recruiting 
6,090 df the intended 9,000 patients, as it was consi&r?d by the- 
ethiizaal review committee that to, continue the study .wu~!I fail 
to.separate, the effect of drug fr& W$ oi @&o, Of,co@xn 
was that’ d&s weti more common, with-’ enal@il ttiah. 
pIacetx$ part&My i? elderly women, btit the &f&m was’. 
‘not significant (Table 1). : ‘. -: 
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dL?&titrast.j& tii; M@aiiiy .Curw& ii sA$-E ‘. 
‘, ‘and CCY5kNS~S 13 t .’ : 
The plabxbo mol$dity ciitv~ I.-r .cONsENSUS:IIis iypixi 
of ah ‘jnfarct pop&ation with hi& de& ,rate in the ‘e&y 
rrto@s approd&ing a plateau by 3 to 2 -n&ths. ,?Wmoti&iIty 
of t&z dru&tr&tefI groip qas higher, &I~ -%iS difference *ai 
not &&tic&y significant. I? SAVE, the mo*:*!lity curves did 
not begin to separate ,.until -‘&lmost 1 year mtc- treatment. 
hjortriiity after presentition with a niyucardiai inti.rGon is 
@g&t hi the first tnonEh, with as many & half of tbesc pat;**~t,s 
dying *thin the fitit few days. Af@ 6 months the influence oi 
the infarction i&nor, an9 the death r&e be&n& $imilar,to 
that fr& m age- and gender-matched populaGon with ischemit 
he& @ease. Fatiure,to see any benefit from captopril in the 
Ed& months of SAVE suggests that t6e bknefit of the di-ug was 
ptiducql through Same long-term mechanism- a&?ing mor- 
tality, although the early tzatment period znay have had an 
,imp&Eant though delayed effect.. Iiuwever, the design of the 
SAVE sttidy is.such that the first 3 days (oi longer) or’ infati 
expansion ajld vent&&r dilatation cannot have been influ- 
e-d by angioten&converti@ enzyme inhibition. Numerous 
explwations for the lack of any apparent benefit from enals- 
pd in CCWENSUS II have been put forward (8). The study 
czmnot e&de either a small benefit or harmful effect of early 
angiot~sih-con~erting enzyme inhibition, but few clinicians 
-Id tiow advocate’the routine,intravenotis I& rif enalaprilat 
in this clinic&! situation. Pubiic$ion of the Acute War&on 
R&ipair Effi&q (AiRE) study has done much to c!srily the 
use of' &ngiotensin-converting enzyme inhibitors after myo~r- 
dial infarcti& (9). 
I 
AmE SfL?d~ 
: ,A group of 2,0045 patients were random@ allocated to 
tre$ment~,~with placebo or the long-acting potent acgiotensin- 
convertirtg ‘enqme inhibitor ramipril in ad&t& to usutii 
treatment (9). FoNti-up was for a tiinimum &f 6 months and 
ah average of 15 months. The primary end point was all-cause 
mortality. Treatment ,was stazed be@een day 3 and day ,I0 
after myocardw infamion (day’l) and on.average at about the 
sixth day. .TQ enter the -&ud-- patients had to have d&finite 
evidenm of. myocardial i@cGon on &mdard electrocardio- 
graphic and enzyme’ criteria and ;clinicai evidence of heart 
fetilure at some time after’admissioi to hospital: P&q&s tii~h 
severe heart fa3& w$e excltided. Caidilnd faiitire (ibdicated 
by a third btiG sound’akd tachytirdi&, rates, at the, bases or 
chest X-ray film) may: have o$y been transiens but wouL 
norma& have rec@ired.treatment+h,a diu:etic or vasod+tor 
drug, for some period; Irideed, the .-intention: W& tliat if a 
clinician nsed ot#y one br two doses of a dietic or Vasodiiator 
dmg or cantintied ~r@~tp~tyt with. +ch drugs for gpparent 
impti~etit’of function and, tbt prescripti9n~ of an ripen-label 
rrngiot~ndn-oatiwflhtg bnzyme inhibit& was not considered 
necessary,’ then the patient was able to be randomized. ; 
The ri& redt+on in all-cause tiortality in patients .rec&- .. 
ing r~miprii was 27% (954-, CI 1 t7b to 407~). The finding was 
highly signiticant OII a tog-;ank test (2p = 0.002). An important 
tinding was that the mortality curves separated earIy, and, 
aiitipi?gh not part of the tirimary analysis, .a ;?resp&ified 
companscrr af early mortality, showed a 29% risk reduction ia 
mortalit) by 30 ddj.: /2r, = O.W?j. 
Predfctfon Qf Outcome A&w 
Myucardial Waretim 
: 
A recent report from Stevenson et .ai. (IO) indicates that 
even with the extensive use of thrombolysis, clinical evidence 
of heart failure is conimon after myocardial infarctiofi atid 
occtirs in some 30% of patients. These patients have a partic 
ularfy poor prognosis, with almost 50% dead by 1 y&r. The 
reports of the Multicenter Postinfarction Group (11): further 
emphasize the prognostic significancq of &mple clinical ;Crite- 
ria. me find& of crackles at the lung bases on auscultation 
was as useful qpredicto: of outcome as eje&ion fraction (Table 
2). Furtherm‘:re, for any given level of ejection fraction, the 
presence of Ainical evidence of heart failure mo& than 
doubles mortality in a p’atinfarction j~puiation. Importantly, 
nearly half of patients CIW manifest clinical evidcnec of failure 
atier myocardinl’ infarction wilt have an ejection fraction 
>41i%. Thiz is. shown clez~ly in a cohort of patients from the 
AiRE study (Fig, 1). .yrhcre -kc: acpr:rage ejection ,fratitiue 
measured by either cardiai, u!tras~nd or .radionuclidem tech- 
nique was :79%: ,Gth .ari, even. distribution arbund this meirn 
value. I-Ioweve.r, Eden in patients not manifesting evidence of 
failure, some 2iYZ ta 2SS will have an ejection fraction (40% 
and ,ti11! fat’! ir;rc, b -mrer pr0grqic goup tiizs. qmptomatic 
patie?& wr+ a n~tial. ejectiqn .fration. Tb target gatienis- at‘ 
h&h risk b;r viflbc cf.-li&*i fai!u&or a Iw; ,ejection fraction 
with dt-wp shoti!.,: mnrked benefit in such &roups has an 
G-action in cost.-effectiveness and avoiding unneces- 






Stndy of Infarcl Survival (lSIS-4) (12) and publication of the 
6-week follow-u? for GISSi-3 (13) go some way toward furtbcr 
dehing the role for These drugs. 
Eotjx the GISS173 ace LB-4 tri& showed that treatment 
-within 24 h with either captopril or lisinopril reduced short- 
term (4 10 6 weeks) mq?aiity, but the effect was small, and 
‘?ven with d&it on ah&t I XXI patients in ISIS4 and ZQOOC 
patients m GISSI-3. sig:lificance levels were only j:M within the 
conventional 5% value (Table 1). No significant benefit was 
found in a study of - 10,UoO patients in China using captopril 
within the first 36 h after myocardial infarction. 
Neither ejection fraction nor symptoms were used to ran- 
domize;. patients into the .GISSIY3 oi ISIS-4 studies, and 
suhgroq$anaiJsis”i ,fra&ht witti difficulti&. Nevertheless, in 
GISSI3 some 75%‘of pit&s du&g’their stay in coronary 
care never manifested clinical evidence tif failure, and this 
group had,an extremely low mortnbty at 6 weeks. No evidence 
of benefit .frog lisinopril was-appareni in these patients. For 
those whd; had cIinica1 evidence .(Killip c&s II or more) of 
failure be!& randomization, ,overail mortality in the ‘coti- : 
.bined lisinopril-treated, atid control patients was suhsta+iak!y 
higher. The: risk reduction in mor@ity a&arent with ‘lisinoprii 
was confir,ed largely to ,tliose manifesting.clin3&l’failure (14). 
A F?nWkabljr similar pattern :ias noted ,ir‘ those with arid 
wi&out .o$er.t failure before randomtition in ISIS-4, e& 
. though the r@s of a &tistical ‘t+t for heterogeneity be- 
tieeti &o@s with and without heart friilure were: negative. 
A&ng t&se patients without app&ent clinical failure entered, 
into GISS!-3 and ISIS4; some 2C% to 25% would be expected : 
to ha%-:a tow ejection fraction and ,the poteritia! for beI& 
b&sea ori the SAW entry Mite& It ,&ems l@ely, ‘therefo$ 
&t phy&iaas using&icql acuqeri and pther a&ssrn+s of 
left vmtricuhu -dysfunction can identify th&e m&t likely to 
: 30%. ,40% 50%. 60% 70% 80% ::- 
Ejedtion Fhlction 
Figure 1. Distribution of ejection fraction at randomization in a short 
of 573 @dents from the Acute M&ion Ramigd Efk.acy (MRE) 
study. 
.,.,.’ 
gain from tr?qtm&t. ‘The unpublished results (see Table 1) of 
the Trandolapril Cardiac Evaluation (TRACE) s&y confirm 
and rx?end the findings of the AIRE and SAVE studies, 
strongly szrpporting ihis approa&. Imp&antly, careful selec- 
tion may also protect some from harm (X5). 
Of major clinicai concern m~sl be the opti& timirlg of 
treatment with angioteqsin-converting e*e inhibitors .after 
myocardial in’ftiction as well as the s&letition of patients. One 
approach would be to trea! ail ‘patients :within fhe first 24 h as 
in ISIS-4 tid~GISSI-3;Ho*~evet, ifthe prot&oIs of these triz!~ 
were followed in their entirety, the treatment ‘should all be 
&thdrWn at’ between -4 &d 6 we&s. These strategies tie 
adopted tb test the abilitjr of &a& I;outine trcatmeot to.p&+nt 
the occurrence’.of late morbidity ‘and mortali,tyty; Currently .the 
only available data regarding this issue are from ,the GJW-3 
trial 6-mbnth foll@+p datti @sented to tL LEuryean :soCC 
ety of Cardiology’.in EMIn (September 1994): &l-cause jmot- 
tality at 6’ weeks was 7.1% and 6.3% ‘(bpen&ntroI: and, 
l&inopnl gr&ps), a difference Of o.ec;/.,However,-iat.B tiontlq 
if@ ‘h+ .with+awal pba$ of the $ujy, this differtine was 
i~dud. to Od%‘(open iXmt*l mortality 9.5% ,l@inupriI mor- 
tality 9lsb), These’ figures indicate .@at between.6 weeks and 
6: qtoniI& there was’ an aid1 exc& mod&y in li&mpril- 
-;--: 
t&ted patients (-4 deaths/@OtIp~tients, t&ed). Nd s&is@ 
ha&been &ported-for this difference,‘$thoFgh it is tisurnedjto 
be norisiggificant. ,The XSX$? &tio~th,,mortality figures are 
curen@-*uwn, h.th.i light of &i;abTe data; the v&ue’of 
a generalized, Mediate, short-term str$&y for ‘ACE’ 
inhibitor therapy a&+ acute rpyo&W infarction ‘remaitis far 
frmpro~n.. ., ;. ,” :; ;j 
ILn the AlREstudy,.benefit was apnt yhether @tier@ 
were randciniized before or a.@er the fifth ‘day; land patients in 
SAW did not deceive thtirapy .until on a&age 11 days after 
infarctw. In both of these &dies patients were in clinically 
stable condition at randomization, and treatment was contin- 
ued indefmitely unless intolerance developed. Although early 
treatm&i.still seems de&bi&, delay iri, administintion beyond 
the f&t day &&cs assessment of cl&a! -stability and idenii- 
f&xtion of patients.most likely to benefit more certain and 
&&dd seem prudent. 
What does not. appear contentious k Iha2 angi&~:nsm- 
convqting en@me in&ibition offers real benefit beyond that of 
cur&t converitiond treatment. The evidence from the SAVE 
a&d AXE trials is that btinefit.ftim an angiutensin-ctinverting 
‘enzyme inhibitof is additive to that: of thrombolysis, aspirin and 
b$a-blockade’. 
Mire than j@ of AIRE study patLnts were receiving 
beta-adrenergic bI@.ing agent thekapy af time of randomiza- 
t&n despite having manifest dinical evidence of ieft ventricular 
dy&nction. lGrthcrmor& in. the SAVE trial, ~30% of pa- 
tients received treatment 4th B beta-bloc&~, These figures 
:indicate that it is not simply a choice of either beta-blocker or 
angioten&n-c~nver&ng enzyme inhibitor therapy but teai I! a 
: significant ‘number ol patienw L,. ~1; ZST;.ciriS suould be used 
@xx&mitMly. The occurrence,of only transient signs of heart 
failhe : may represent one .c!ear indication to consider com- 
,b*d therapy,, altho&h x+nptomatic’reduction of ejeciio? 
fraction may represent &i even greaie’r proportion of p&ients 
in whom a~& a~;, approach shotid be-c&id&red. 
The roie ot e@y :ntraverrOllS nitrate therapy seemed dear 
&fore the GISW3 and ISIS4 -trials on the basis of the 
r@ta-analysis of Y u5uf et al. (16) performed in i.988, This was 
consistent withIanima1 data, leading to the pretfiaJ premise 
that nitrate therapy wouM red& aerse ventriculk remod- 
,eiing and’ thereby, impr?ve survival. ,In GiSSI3 .tkie overal! 
effect of intraverqs foIlowed by ,cutaneous nitrate theiapy was 
a ncCgniMt ,tpnd tow&d benefit ‘(13); However, failure tb 
“achieve statistitil xign&ance may have ‘been b&auk &% cf 
control subjects were also giyen eayly jntraveeous therapy. FQ~ 
this reason tibservers have @@idned the -‘validiZy of the 
’ GISSI-3 result (17).‘Unfortu@ately, the.,ESIS-Q trial ad+ ‘1ittLe 
to’ this partic& debate, as agairi &lose to. half the placebo 
group received, intkenous nitrate trq&nent; Certainb, ,inira:, 
venous, nitrak therapy appears ‘to offer-a tiore &ntrbllabte. 
means of reduc& cardiac afterload than, does &nmedkte 
angiOtensin-converting enzyme inhibitor therapy with clear 
-:; 
j., 
chical inc@t&ns for use in symptomatic h&rt faiI& 




patiknts with clitiiqal e\iidence (e&f transient) ‘of failure 
after myo.cardia infarctiob a& those with reduced’ijection 
fraction have’tiuch to’gain from t@tment with,zin an&iotetiin- 
converting enzyme inhibitor. For’some pat&s benefit,may be, 
ap$Wnt early, ‘atid ihere iseemT no’j&tifica& for delaying 
treatment: However, to be prepared to &it 524 h $0 ensure 
reasonable -clinical stsbiiity seems appropriate to maximize 
poten?ial benefit against potential risk, Absence of czdiogenic 
shot@ and F&e presence of reasonable cli#al sta@ity with 
the .perCei\ied need for a:diuretic br vasodilritor, 07 objective 
evidence of si@ificant left ventricuik impairment, are 
now synx~ymous with the requirement for an angiotenst:- 
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